Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Retained Earnings (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Retained Earnings readings, the most recent being -$101.3 million for Q4 2024.

  • On a quarterly basis, Retained Earnings fell 57.01% to -$101.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$101.3 million, a 57.01% decrease, with the full-year FY2024 number at -$101.3 million, down 57.01% from a year prior.
  • Retained Earnings hit -$101.3 million in Q4 2024 for Unicycive Therapeutics, down from -$79.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$15.9 million in Q4 2021 to a low of -$101.3 million in Q4 2024.
  • Median Retained Earnings over the past 4 years was -$52.4 million (2023), compared with a mean of -$52.7 million.
  • Biggest five-year swings in Retained Earnings: crashed 149.39% in 2023 and later crashed 40.64% in 2024.
  • Unicycive Therapeutics' Retained Earnings stood at -$15.9 million in 2021, then crashed by 113.29% to -$34.0 million in 2022, then crashed by 89.72% to -$64.5 million in 2023, then crashed by 57.01% to -$101.3 million in 2024.
  • The last three reported values for Retained Earnings were -$101.3 million (Q4 2024), -$79.7 million (Q3 2024), and -$75.6 million (Q2 2024) per Business Quant data.